Latest Bambusa Therapeutics News & Updates

See the latest news and media coverage for Bambusa. We track all announcements, press releases, and industry mentions in real time, all in one place.

Bambusa Therapeutics (Bambusa)

Clinical-stage biotechnology company

bambusatx.com

Headquarters: BOSTON, United States
Founded year: 2024
Company type: Private company
Number of employees: 20–50

Last updated Today

Latest news about Bambusa Therapeutics (Bambusa)

In short: Bambusa advanced its bispecific antibody pipeline, reporting positive Phase 1 data for BBT001 and BBT002 while securing Series A and A-2 funding.

Company announcements

June 15 Bambusa

Bambusa announces positive Phase 1 data for BBT002

The bispecific antibody targets IL-4Rα and IL-5, showing sustained biomarker effects for 8 weeks.

May 18 Bambusa

Bambusa reports positive Phase 1 data and begins new trial

The antibody showed depletion of eosinophils, and the Phase 1b/2a trial is for chronic rhinosinusitis with nasal polyps.

May 1 Bambusa

Bambusa completes enrollment in BBT001 trial

The Phase 1b/2a trial targets moderate-to-severe atopic dermatitis. Topline results are expected in mid-2026.

March 17 Bambusa

Bambusa announces Phase I data acceptance for BBT001

Data will be presented as an ePoster at AAD 2026 Annual Meeting. Company highlights rapid execution and best-in-class PK/PD profiles.

Media coverage

June 15 Yahoo Finance

Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual ...

Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation, long-acting bispecific antibodies for immunology and inflammation, today announced ...

May 18 Yahoo Finance

Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed ...

Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation, long-acting bispecific antibodies for immunology and inflammation, today announced the presentation of preliminary data...

April 30 The Manila Times

Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis

Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and commercially validated targets, IL-4Rα and IL-31 for the treatment of...

April 1 BioSpace

Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting - BioSpace

Immunogenicity: The incidence of ... safety or PK. "We were excited to highlight the data from our BBT001 clinical program for the first time at...

Never miss news about Bambusa

Track Bambusa and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Bambusa competitors & trending companies

Browse news for competitors to Bambusa and other trending companies.